Merck & Co., Inc.

Merck & Co., Inc.

February 06, 2006 11:00 ET

Lakeland Regional Cancer Center Licenses the Rosetta Resolver Expression Data Analysis System

LAKELAND, Fla., and SEATTLE--(CCNMatthews - Feb 6, 2006) -

Lakeland Regional Cancer Center and Rosetta Biosoftware announced today that Lakeland Regional Cancer Center licensed the Rosetta Resolver® system to investigate the clinical value of microarrays for assisting in cancer staging, the process of describing the severity of a cancer at the time of diagnosis.

"The Resolver system is a comprehensive and scalable informatics solution that addresses the gene expression data analysis and management needs for biomarker discovery in cancer research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "We are pleased to provide Lakeland Regional Cancer Center with tools to advance research in facilitating prognosis on a molecular level."

"In our Molecular Staging Laboratory, we test the clinical value of various molecular assays for cancer staging," said Steven C. Shivers, Ph.D., associate director for basic science and translational research and director of the Molecular Staging Laboratory at Lakeland Regional Cancer Center. "The Resolver system will be an important tool for investigating the clinical value of oligonucleotide microarrays. The reliability and flexibility of the Resolver system will benefit various cancer staging applications, including the discovery of prognostic and/or therapy-responsive biomarkers."

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

About Lakeland Regional Cancer Center

Lakeland Regional Cancer Center is committed to delivering exceptional cancer care through prevention, early detection, treatment, research, and the relentless pursuit of a cure. Lakeland Regional Cancer Center is a community oncology resource and proudly claims an international leadership position in cancer research and patient care. By conducting research in molecular chemistry laboratories, actively participating in clinical trial protocols, and networking with major cancer centers, Lakeland Regional Cancer Center stands at the forefront with the latest treatment advances. Every day, cancer patients throughout the world benefit from their unwavering commitment to research and its promise of hope. Truly patient-focused, Lakeland Regional Cancer Center provides highly skilled and compassionate physicians who specialize in Surgical Oncology, Radiation Oncology, Medical Oncology and Hematology, and Urology.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

Contact Information

  • For Rosetta Biosoftware
    Lisa Owen, 206-926-1236
    For Lakeland Regional Cancer Center